Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe study's locations list was updated to reflect fewer active sites: the page now shows 39 locations, and several previously listed sites (e.g., Busan, Michalovce, Cebu, San Luis Potosí City, Mexico City, and other Mexican sites) were removed.SummaryDifference0.6%

- Check10 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor version update. This update does not modify the study details or listed locations.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check38 days agoChange DetectedThe study expanded its locations to 44 sites across multiple countries, adding Busan (South Korea), Michalovce (Slovakia), Cebu (Philippines), San Luis Potosí City (Mexico), and Mexico City (Mexico). This broadens geographic participation and potential enrollment for the trial.SummaryDifference0.6%

- Check45 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This update appears to reflect behind-the-scenes maintenance rather than changes to study details.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page revision label was updated from v3.6.1 to v3.6.3, indicating a newer deployment of the page template.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision: v3.6.1 replaces the previous v3.6.0 on the page. This indicates a small update to the page’s revision metadata rather than changes to the study content.SummaryDifference0.0%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.